IMS Company Profiles - Report Buyer

IMS COM PANY PRO FILES NOVARTIS
Company/Organization Date Area of
Collaboration
Ascent Therapeutics 2008 Pepducin drug
candidates against a
specific G-protein
coupled receptor
(GPCR) target
Evotec 2008 Small molecule
therapeutics for
central nervous
system (CNS)
Egalet 2008 Parvulet drug
delivery technology
Terms of Agreement
© 2009 IMS Health In cor po rated or its af fil i ates Page 130
Licensing option agreement through the
Novartis Option Fund. AT will develop
Pepducin drug candidates against a
specific GPCR target. Agreement includes
an upfront fee, potential milestone
payments (possible $200m), and royalties.
AT’s Pepducin technology comprises a
short peptide derived from a GPCR
intracellular loop tethered to a
hydrophobic moiety. The technology is
capable of inhibiting or activating multiple
signals in GPCR pathways; this is a
mechanism for disrupting GPCR signal
transduction from inside the cell surface,
facilitating the treatment of a wide range
of conditions.
Research collaboration for an initial three
years. Evotec will use its drug discovery
platform to advance a drug discovery
program against a target nominated by
Novartis from discovery into the clinic. The
programs will be developed to the
preclinical stage by Evotec; Novartis will
then be responsible for all clinical
development activities, manufacture and
commercialization of the compounds.
Evotec is eligible for an upfront payment,
milestone payments which could total
more than $28 m, and royalties.
Egalet (Denmark) granted Sandoz (part of
Novartis) a worldwide license to Parvulet,
an oral drug delivery technology
comprising a sealed dispensing spoon
containing the relevant drug in a
formulation requiring hydration. Sandoz
will utilize Parvulet to develop a pediatric
formulation of an undisclosed compound.
Under the terms of the deal Egalet will
receive an upfront payment, a milestone
payment and royalties from sales.